Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
20 participants
OBSERVATIONAL
2024-03-31
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Glucagon is a natural hormone that controls how the body stores and uses fuel. Glucagon acts on liver cells to use protein and fat to make sugar. It decreases the amount of liver fat.
The investigators think that patients with MASLD may not respond to the actions of glucagon. This could contribute to the build-up of fat in the liver.
In this study the investigators will be investigating the effects of glucagon on protein breakdown and sugar production in patients with and without MASLD.
Healthy volunteers and patients with MASLD will attend for one study visit each which will last for 4-5 hours. During this time they will have infusions into a vein of glucagon and other hormones, amino acids (to mimic the fed state) and 'tracers'. From another vein they will have several blood samples during this period. By analysing these blood samples the investigators will be able to measure the effects of glucagon on protein and glucose turnover (metabolism), and whether this differs between healthy volunteers and those with MASLD.
If the investigators find that patients with MASLD are resistant to the actions of glucagon, this could help with the development of drugs to treat MASLD.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Screening visit:
During this visit that will last around an hour, prospective participants will have a consultation with a study doctor. The doctor will assess medical history and explain the study. They will also perform a routine physical examination and take some blood tests. Women of child-bearing age will undergo urinalysis to exclude pregnancy. Participants will be contacted a couple of days later to let discuss blood test results, and if these are satisfactory they will be invited to attend for 1 study visit.
Study visit:
Participants will be asked to avoid alcohol and strenuous exercise for 24 hours before the study visit. They will be asked to fast (that is, consume nothing except water) for 10-14 hours before the visit. The visits will start at around 8 or 9am and finish at about 1 or 2pm.
On arrival, female volunteers will be asked for a urine specimen which will be tested for evidence of pregnancy. Participants will be weighed and have pulse, blood pressure and temperature checked.
The participant's arms will be loosely wrapped in a heating pad (50°C). A study investigator will insert two cannulae (thin flexible tubes) into a vein in each arm. One cannula will be used for infusions and the other for blood samples. The investigators will infuse glucagon and two other hormones (insulin and somatostatin), amino acids (to mimic the 'fed state') and 'tracers' of an amino acid called alanine and glucose. The investigators will take multiple blood samples at intervals during the infusions to measure the levels of hormones, sugar and protein in the blood. The total amount will be less than 200ml (around 11 tablespoons), which is less than half the amount taken during a blood donation session.
After 3.5 hours the cannulae will be removed, the participant will be offered something to eat, and after 15-30 minutes of observation they will be allowed to leave the unit. During the study participants can watch TV or read. They will not be able to eat but they can sip water.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy volunteer
Subject without MASLD or metabolic-associated disease
Acute glucagon infusion
All subjects will undergo an amino acid infusion and pancreatic clamp during which they will have stable isotope turnover of glucose and alanine measured in two steady state periods - firstly, with low-dose glucagon infusion and secondly, with high-dose glucagon infusion
MASLD
Subject with MASLD
Acute glucagon infusion
All subjects will undergo an amino acid infusion and pancreatic clamp during which they will have stable isotope turnover of glucose and alanine measured in two steady state periods - firstly, with low-dose glucagon infusion and secondly, with high-dose glucagon infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acute glucagon infusion
All subjects will undergo an amino acid infusion and pancreatic clamp during which they will have stable isotope turnover of glucose and alanine measured in two steady state periods - firstly, with low-dose glucagon infusion and secondly, with high-dose glucagon infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to give full informed consent
* 18 years old or more (children have different metabolism)
• Biopsy-proven or clinically diagnosed MASLD (\>5% steatosis)
Exclusion Criteria
* Pregnant or breastfeeding (affects metabolism)
* Recent weight loss or gain (\>10% in previous 3 months)
* History of hypersensitivity to any of the infusates listed in the study design
* Diabetes or pre-diabetes (HbA1C \>42mmol/mol)
* Consumption of over 14 units of alcohol per week
* Evidence of metabolic syndrome
* Previous or current clinical or biochemical evidence of liver disease
* Evidence of liver cirrhosis
* Non-metabolic associated causes of liver disease (e.g. viral hepatitis)
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imperial College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emma Rose McGlone, PhD
Role: PRINCIPAL_INVESTIGATOR
Imperial College London
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
334557
Identifier Type: -
Identifier Source: org_study_id